Basilea Pharmaceutica Ltd

Activities: Research & Development

Trending Articles

  1. ICROM has acquired HOLODIAG ICROM srl, an italian API CDMO, has acquired the French-based Contract Research Organization HOLODIAG sas specialized in solid state studies and crystallization services of...
  2. Lonza completes Visp microbial manufacturing facility expansion The company now hosts two 4,000L fermenters on its cGMP-compliant site, which was expanded due to the growing industry demand for biologics
  3. At CPHI Milan, TekniPlex Healthcare to Highlight New Solutions for Single-use Bioprocessing, Cell & Gene Therapies Company also will provide live demos of next-generation automatic filler-sealer for single-dose plastic vials, and showcase sustainability-minded blister packaging, as well as...
  4. PolTREG's Treg cell therapy exhibits long-term clinical remission in type 1 diabetes patients The clinical-stage biotech's lead candidate, PTG-007, has demonstrated its ability to induce clinical remission in T1D patients for up to 12 years
  5. Vetter manufactures first 100 clinical vial batches at its Austria site The CDMO has successfully completed the production of 100 liquid and lyophilised clinical batches for global clients

Upcoming event

Boston Biotech Week

23-26 September, 2024 | Convention and exhibition | Boston, US See all

Related Content

Research & Development

Spexis sells preclinical antibiotics programme to Basilea

The CHF 2m deal gives Basilea ownership of a novel programme of Gram-negative bacteria-targeting antibiotics
Finance

Spexis announces sale of preclinical antibiotics programme to Basilea

Basilea to pay up to CHF2m for a preclinical programme with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains
Research & Development

Forge and Basilea partner on antibiotic discovery

Forge Therapeutics’s platform will be used by Basilea Pharmaceutica to develop inhibitors against two historically difficult-to-drug, unexploited antibiotic targets
Research & Development

Basilea awarded up to US$100m contract from BARDA

To advance clinical Phase III programme for ceftobiprole antibiotic
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Latest EU drug approvals span range of health issues

Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Research & Development

Basilea's Chief Technology Officer to retire

Dr Günter Ditzinger named as successor Dr Ingrid Heinze-Krauss
Research & Development

Consortium signs deal with Basilea to develop targeted cancer therapy

Clinical Phase I testing of panRAF kinase inhibitors is expected to start this year
Subscribe now